Semax and Selank one-week reviews: what TikTok gets wrong

What's this video probably claiming?

Based on the caption and hashtag context, @bethanyjoy6 is almost certainly walking through a first-week personal experience with semax and selank, two synthetic peptides originally developed in Russia. The framing, "might just change the game for me," is a soft but loaded claim. It implies noticeable cognitive or anxiolytic effects within seven days, possibly describing improved focus, reduced anxiety, or a calmer mental state. The tag to two other creators suggests this is part of a broader social thread where people are swapping anecdotes about peptide stacks. Week-one reviews of nootropic peptides tend to follow a predictable script: initial excitement, reports of "mental clarity," reduced brain fog, or a noticeable mood shift. Whether she's also talking about dosing protocols, administration method (nasal spray is common for both), or sourcing is unclear without the transcript. What we can say upfront: a one-week self-report from a single person, no control condition, no baseline measurement, tells us almost nothing clinically useful.

What does the science actually show?

Semax (ACTH 4-7 Pro-Gly-Pro) and selank (a tuftsin analog, Thr-Lys-Pro-Arg-Pro-Gly-Pro) were both developed at the Institute of Molecular Genetics in Moscow and have been used clinically in Russia and Ukraine, primarily for cognitive impairment and anxiety. That's where much of the evidence stops. A 2011 study by Dolotov et al. in the Journal of Neurochemistry showed semax increased BDNF and NGF expression in rats, which sounds compelling until you remember rodent neurochemistry does not translate cleanly to human clinical outcomes. Human trials on semax are limited, small, and mostly conducted in Russian-language literature, with sample sizes often under 60 patients. Selank has slightly more anxiety-focused data: a 2014 randomized trial by Zozulya et al. published in Neuroscience and Behavioral Physiology (n=60) found selank 400 mcg intranasal reduced anxiety scores comparably to a low-dose benzodiazepine over four weeks, but the study has not been independently replicated in larger Western cohorts. Neither peptide is FDA-approved. The mechanistic story, BDNF upregulation, GABAergic modulation, is plausible. The clinical evidence is thin.

Where does the social media noise diverge from clinical reality?

TikTok peptide content almost always conflates "mechanism looks interesting in a lab" with "this will work for you." A few specific gaps worth naming. First, the one-week timeline problem: semax's proposed BDNF-related effects, if real in humans, would not plausibly peak at day seven. The Zozulya selank trial ran four weeks before showing significant anxiolytic effects. Reporting transformation after seven days is almost certainly placebo response, expectation bias, or simply the stimulating effect of trying something new. Second, most semax and selank sold through peptide vendors in the U.S. is research-grade, meaning it is not manufactured under pharmaceutical-grade GMP standards. Purity, potency, and sterility are not guaranteed. Third, nobody on TikTok is disclosing that these are unapproved substances in the U.S. with no established safety profile in long-term human use. The word "nootropic" launders a lot of regulatory uncertainty into something that sounds like a wellness supplement.

What should you actually know?

If you are considering semax or selank because a TikTok review made them sound like a clean cognitive upgrade, here is what the actual picture looks like. Both peptides have a genuinely interesting mechanistic profile, and the Russian clinical data, while limited by Western research standards, is not fabricated. Semax in particular has been studied in ischemic stroke patients (Lebedeva et al., 1995, Zhurnal Nevrologii i Psikhiatrii) and showed some benefit in cognitive recovery, but those are acute neurological patients, not healthy adults optimizing focus. Selank's GABAergic and serotonergic modulation may have real anxiolytic potential, but "may have" is doing heavy lifting there. Neither peptide has undergone large-scale Phase III trials by Western regulatory standards. Side effect profiles are poorly characterized. Sourcing from gray-market vendors adds a layer of risk that no one in this TikTok thread is discussing. A telehealth provider who prescribes compounded peptides should be doing a thorough intake, monitoring labs, and not relying on social media stacks as clinical guidance.